Originally posted in Medical News Today by Marie Ellis
Results from the study were presented earlier this year at the American Epilepsy Society’s Annual Meeting in Philadelphia, PA, but this is the first time the findings have been published in a peer-reviewed journal – The Lancet Neurology.
Cannabidiol (CBD) is one of many compounds in cannabis that belong to a class of molecules known as cannabinoids. CBD and tetrahydrocannabinol (THC) are typically present in marijuana in the highest concentrations.
THC, however, has psychoactive properties, whereas CBD is free from such side effects.
CBD has been investigated in recent years for its positive effects on people with epilepsy, a brain disorder that causes seizures. According to the latest estimates, around 5.1 million children and adults in the US have had an epilepsy diagnosis or seizure disorder.